Evidence map›Paper›PMID 40626411›Full record

ArticleThe Cochrane database of systematic reviews2025

Complement inhibitors for myasthenia gravis in adults.

Laura M White, Fiona J Clay, Anne-Marie Forbes, Ryan Yann Shern Keh, James B Lilleker, Jennifer Spillane, Karen Storms, Jon Sussman, Katherine C Dodd

Abstract read
In one paragraph

Article in The Cochrane database of systematic reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Laura M WhiteLancaster Medical School, Lancaster University, Lancaster, UK.
Fiona J ClayDepartment of Forensic Medicine, Monash University, Southbank, Australia.
Anne-Marie ForbesCreative Arts & Health - School of Creative Arts & Media, University of Tasmania, Hobart, Australia.
Ryan Yann Shern KehManchester Centre for Clinical Neurosciences, Northern Care Alliance NHS Foundation Trust, Salford, Greater Manchester, UK.
James B LillekerManchester Centre for Clinical Neurosciences, Northern Care Alliance NHS Foundation Trust, Salford, Greater Manchester, UK.
Jennifer SpillaneNational Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, London, UK.
Karen StormsLibrary & Knowledge Service, Northern Care Alliance NHS Foundation Trust, Oldham, UK.
Jon SussmanManchester Centre for Clinical Neurosciences, Northern Care Alliance NHS Foundation Trust, Salford, Greater Manchester, UK.
Katherine C DoddManchester Centre for Clinical Neurosciences, Northern Care Alliance NHS Foundation Trust, Salford, Greater Manchester, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThis is a protocol for a Cochrane Review (intervention). The objectives are as follows: To evaluate the benefits and harms of complement inhibitors for treating myasthenia gravis in adults compared with control treatment (placebo or standard care).

Indexed as

Complement Inactivating AgentsMyasthenia GravisAdultAntibodies, Monoclonal, HumanizedHumansRandomized Controlled Trials as TopicAntibodies, Monoclonal, HumanizedComplement Inactivating Agents

Identifiers

PMID40626411
PMCPMC12235703

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.